Race Oncology Limited (RAONF)

OTCMKTS · Delayed Price · Currency is USD
1.220
+0.390 (46.99%)
Inactive · Last trade price on Jul 11, 2024
46.99%
Market Cap134.20M
Revenue (ttm)3.25M
Net Income (ttm)-4.74M
Shares Outn/a
EPS (ttm)-0.03
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume8,000
Average Volume3,442
Open1.220
Previous Close0.830
Day's Range1.220 - 1.220
52-Week Range0.830 - 1.220
Beta1.92
RSIn/a
Earnings DateAug 26, 2025

About Race Oncology

Race Oncology Limited, a clinical stage biopharmaceutical company, focuses on addressing the unmet needs of cancer patients for damaging treatments. The company’s lead product is bisantrene, a small molecule chemotherapeutic that has a clinical history with demonstrated therapeutic benefits in adult and paediatric patients. It is advancing reformulated bisantrene (RC220) to address the unmet need of patients across various oncology indications with a clinical focus on anthracycline combination to deliver cardioprotection and enhanced anticancer... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2011
Country Australia
Stock Exchange OTCMKTS
Ticker Symbol RAONF
Full Company Profile

Financial Performance

In 2024, Race Oncology's revenue was 4.00 million, an increase of 27.73% compared to the previous year's 3.13 million. Losses were -13.82 million, 39.3% more than in 2023.

Financial numbers in AUD Financial Statements

News

There is no news available yet.